Abeona Therapeutics (ABEO) Stock Forecast, Price & News

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abeona Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ABEO shares.
View ABEO analyst ratings or view top-rated stocks.

1 brokers have issued 1-year price targets for Abeona Therapeutics' stock. Their ABEO share price forecasts range from $38.00 to $38.00. On average, they expect the company's stock price to reach $38.00 in the next year. This suggests a possible upside of 952.6% from the stock's current price.
View analysts price targets for ABEO or view top-rated stocks among Wall Street analysts.

Abeona Therapeutics' stock was trading at $3.08 at the start of the year. Since then, ABEO stock has increased by 17.2% and is now trading at $3.61.
View the best growth stocks for 2023 here.

Abeona Therapeutics saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 500,500 shares, an increase of 13.2% from the August 15th total of 442,000 shares. Based on an average trading volume of 166,400 shares, the short-interest ratio is presently 3.0 days. Approximately 2.2% of the shares of the company are sold short.
View Abeona Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ABEO earnings forecast.

Abeona Therapeutics Inc (NASDAQ:ABEO) announced its quarterly earnings results on Tuesday, August, 8th. The biopharmaceutical company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.22. The biopharmaceutical company had revenue of $3.50 million for the quarter.

Abeona Therapeutics shares reverse split before market open on Tuesday, July 5th 2022. The 1-25 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Abeona Therapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Corbus Pharmaceuticals (CRBP), OPKO Health (OPK), Sangamo Therapeutics (SGMO), Energy Transfer (ET), Sorrento Therapeutics (SRNE), Micron Technology (MU), TherapeuticsMD (TXMD), VBI Vaccines (VBIV) and Advanced Micro Devices (AMD).

Abeona Therapeutics trades on the NASDAQ under the ticker symbol "ABEO."

Abeona Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Point72 Asset Management L.P. (6.02%), Goldman Sachs Group Inc. (1.14%), Citigroup Inc. (1.06%), Geode Capital Management LLC (0.84%), BlackRock Inc. (0.76%) and Northern Trust Corp (0.55%). Insiders that own company stock include Brendan M O'malley, Edward Carr, Joseph Walter Vazzano, Mark Alvino, Michael Amoroso, Paul Elliot Mann, Sco Capital Partners Llc and Todd Wider.
View institutional ownership trends.

Shares of ABEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ABEO stock can currently be purchased for approximately $3.61.

Abeona Therapeutics (NASDAQ:ABEO) has a market capitalization of $89.38 million and generates $1.41 million in revenue each year.

Abeona Therapeutics' mailing address is 3333 LEE PARKWAY SUITE 600, DALLAS TX, 75219. The official website for the company is www.abeonatherapeutics.com. The biopharmaceutical company can be reached via phone at 214-665-9495, via email at ir@abeonatherapeutics.com, or via fax at 214-905-5101.